MARIKA, INC.Subscription Agreement • September 30th, 2013 • Marika Inc. • Services-business services, nec
Contract Type FiledSeptember 30th, 2013 Company Industry
Exhibir 10.1 SERVICES AGREEMENT - ERRAND/CONCIERGE THE PARTIES TO THIS AGREEMENT ARE: "Marika Inc ." 2360 Corporate circle, suite 400, Henderson NV 89074 The Client " Superakcijas " A.Kalnina1a-8, Riga Latvia Marika Inc. hereby agrees to provide...Services Agreement • August 20th, 2013 • Marika Inc.
Contract Type FiledAugust 20th, 2013 Company
5,500,000 Shares Pieris Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 14th, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledFebruary 14th, 2018 Company Industry Jurisdiction
OPEN MARKET SALE AGREEMENTSM August 9, 2019 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated...Pieris Pharmaceuticals, Inc. • August 9th, 2019 • Services-commercial physical & biological research • New York
Company FiledAugust 9th, 2019 Industry Jurisdiction
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 6th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
Contract Type FiledJune 6th, 2016 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of June 2, 2016, by and among Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the several signatories hereto.
Shares Pieris Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 24th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledJune 24th, 2015 Company Industry JurisdictionPieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional shares (the “Option Shares”) of Common Stock from the Company for the purpose of covering over-allotments in connection with the sale of the Firm Shares. The Firm Shares and the Option Shares are collectively called the “Shares.”
PIERIS PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENTCommon Stock • October 5th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledOctober 5th, 2016 Company Industry JurisdictionPieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
SPLIT-OFF AGREEMENTSplit-Off Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec • New York
Contract Type FiledDecember 18th, 2014 Company Industry JurisdictionThis SPLIT-OFF AGREEMENT, dated as of December 17, 2014 (this “Agreement”), is entered into by and among Pieris Pharmaceuticals, Inc. (f/k/a Marika Inc.), a Nevada corporation (“Seller”), Marika Enterprises Inc., a Nevada corporation and wholly owned subsidiary of Seller (“Split-Off Subsidiary”), and Aleksandrs Sviks (“Buyer”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec • Nevada
Contract Type FiledDecember 18th, 2014 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this day of , 2014, by and between Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and (“Indemnitee”).
COMMON STOCK PURCHASE WARRANT PIERIS PHARMACEUTICALS, INC.Pieris Pharmaceuticals, Inc. • December 23rd, 2014 • Services-commercial physical & biological research
Company FiledDecember 23rd, 2014 IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December , 2014 (the “Initial Exercise Date”) but not after 5:00 p.m. (New York time) on December , 2019 (the “Termination Date”), to subscribe for and purchase from PIERIS PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), up to ( ) shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). At 5:00 pm (New York Time) on the Termination Date, this Warrant shall become void and of no value.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 23rd, 2014 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledDecember 23rd, 2014 Company Industry JurisdictionThis Agreement is made pursuant to (i) the Securities Purchase Agreement, dated as of December 17, 2014, between the Company and each Person listed on the signature pages thereto (the “Purchase Agreement”), and (ii) the Acquisition Agreement, dated December 17, 2014, by and among the Company, Pieris AG, a stock corporation formed under the laws of Germany, and the share and note holders of Pieris AG listed on the signature pages thereto (the “Acquisition Agreement”).
ContractEmployment Agreement • November 2nd, 2021 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 2nd, 2021 Company Industry Jurisdiction
CONFIDENTIAL TREATMENT REQUESTEDConfidential Treatment Requested • July 31st, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledJuly 31st, 2018 Company Industry JurisdictionThis License and Collaboration Agreement is entered into as of February 8, 2018 (the “Effective Date”) by and among Seattle Genetics, Inc., a Delaware corporation located at 21823 30th Drive SE, Bothell, WA 98021 (together with its Affiliates, “SGEN”), and Pieris Pharmaceuticals, Inc., a Nevada corporation located at 255 State Street, 9th floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a company organized and existing under the laws of Germany located at Lise-Meitner-str. 30, 85354 Freising, Germany (collectively and together with their Affiliates, “PIRS”). SGEN and PIRS are individually referred to herein as a “Party” and collectively, as the “Parties”.
PUBLIC COMPANY SUPPORT AGREEMENTPublic Company Support Agreement • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 24th, 2024 Company Industry JurisdictionThis Support Agreement (this “Agreement”) is made and entered into as of July 23, 2024, by and among Palvella Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Pieris Pharmaceuticals, Inc., a Nevada corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Public Company.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJuly 24th, 2024 Company Industry JurisdictionThis SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 23, 2024, by and among Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on Exhibit A hereto and each Convertible Note Purchaser (as defined below) who becomes a party to this Agreement in accordance with Section 6.1 below (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ACQUISITION AGREEMENTAcquisition Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec
Contract Type FiledDecember 18th, 2014 Company IndustryTHIS ACQUISITION AGREEMENT (“Agreement”) is made and entered into as of December 17, 2014 (the “Execution Date”), by and among: PIERIS PHARMACEUTICALS, INC. (f/k/a Marika Inc.), a Nevada corporation with its registered office located in Henderson, Nevada (“Parent”); PIERIS AG, a stock corporation formed under the laws of Germany with its registered office in Freising, Germany, and registered with the commercial register (Handelsregister) of the local court of Munich (the “Commercial Register”) under HR B 133223 (the “Company”); and the shareholders of the Company listed on Exhibit B, attached hereto (the “Holders”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
LICENSE AND COLLABORATION AGREEMENT BETWEEN LES LABORATOIRES SERVIERLicense and Collaboration Agreement • April 26th, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
Contract Type FiledApril 26th, 2018 Company IndustryThis License and Collaboration Agreement is entered into as of January 4, 2017 (the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France and Institut de Recherches Internationales Servier, a company duly organized and existing under the laws of France having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France (individually and collectively, “Servier”), and Pieris Pharmaceuticals, Inc., a Nevada corporation having offices and principal place of business at 255 State Street, 9th floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a company organized and existing under the laws of Germany having offices and principal place of business at Lise-Meitner-str. 30, 85354 Freising, Germany (individually and collectively, “Pieris”). Servier and Pieris are individually referred to herein as a “Party” and coll
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT by and among PIERIS PHARMACEUTICALS, INC., SHAREHOLDER REPRESENTATIVE SERVICES LLC, as the Holder Representative, and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A., acting jointly as Rights Agent...Contingent Value Rights Agreement • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 24th, 2024 Company Industry JurisdictionThis CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [●], 2024 (this “Agreement”), is by and among Pieris Pharmaceuticals, Inc., a Nevada corporation (“Public Company”), Computershare Inc., a Delaware corporation (“Computershare”) and its affiliate Computershare Trust Company, N.A., a federally chartered trust company (together with Computershare, the “Rights Agent”), and Shareholder Representative Services LLC, a Colorado limited liability company (the “Holder Representative”), acting solely in its capacity as the representative, agent and attorney-in-fact of the Holders (as defined below), in favor of each Person who from time to time holds one or more contingent value rights to receive the Payments (as defined below) upon the occurrence of one or more CVR Events (as defined below) (each such contingent value right, a “CVR”), subject to the terms and conditions set forth herein. Each of the parties hereto shall be referred to as a “Party” and, collectively, as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED LICENSE AND TRANSFER AGREEMENTLicense and Transfer Agreement • July 20th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledJuly 20th, 2016 Company Industry JurisdictionThis license and transfer agreement (the “Agreement”) is entered into with effect as of April 18, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
Pieris Pharmaceuticals, Inc. Series F Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENTSubscription and Investment Representation Agreement • August 8th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledAugust 8th, 2024 Company Industry JurisdictionTHIS AGREEMENT, dated as of August 7, 2024, is by and between Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, the parties hereto agree as follows:
MERGER PARTNER SUPPORT AGREEMENTMerger Partner Support Agreement • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 24th, 2024 Company Industry JurisdictionThis Support Agreement (this “Agreement”) is made and entered into as of July 23, 2024, by and among Palvella Therapeutics, Inc. a Delaware corporation (“Merger Partner”), Pieris Pharmaceuticals, Inc., a Nevada corporation (“Public Company”), and the undersigned stockholder (the “Stockholder”) of Merger Partner.
DEVELOPMENT AND LICENSE AGREEMENTConfidential Treatment Requested • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledMarch 30th, 2015 Company Industry JurisdictionTHIS LICENSE AGREEMENT (the “Agreement”) is made and is effective as of this 7th day of October, 2013 (the “Effective Date”) by and between
AGREEMENT AND PLAN OF MERGER by and among PIERIS PHARMACEUTICALS, INC., POLO MERGER SUB, INC. and PALVELLA THERAPEUTICS, INC. Dated as of July 23, 2024Agreement and Plan of Merger • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 24th, 2024 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of July 23, 2024, is entered into by and among Pieris Pharmaceuticals, Inc., a Nevada corporation (“Public Company”), Polo Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Public Company (the “Merger Sub”), and Palvella Therapeutics, Inc. a Delaware corporation (“Merger Partner”).
FORM OF LOCK-UP AGREEMENTLock-Up Agreement • July 24th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
Contract Type FiledJuly 24th, 2024 Company IndustryThe undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Pieris Pharmaceuticals, Inc., a Nevada corporation (“Public Company”), has entered into an Agreement and Plan of Merger, dated as of July 23, 2024 (as the same may be amended from time to time, the “Merger Agreement”) with Polo Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Public Company, and Palvella Therapeutics, Inc. a Delaware corporation, a Delaware corporation (“Merger Partner”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • April 26th, 2018 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
Contract Type FiledApril 26th, 2018 Company IndustryTHIS NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of January 4, 2017 (the “Effective Date”), by and between PIERIS PHARMACEUTICALS, INC., a Nevada corporation having its principal place of business at 255 State Street, 9th floor, Boston, MA 02109 AND PIERIS PHARMACEUTICALS GMBH, a company organized and existing under the laws of Germany having offices and principal place of business at Lise-Meitner-str. 30, 85354 Freising, Germany (collectively, “Pieris”), and LES LABORATOIRES SERVIER, a corporation incorporated under the laws of France having a principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France and INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France (collectively, “Licensee”). Pieris and Licensee each may be referred to herein individually a
CONFIDENTIAL TREATMENT REQUESTED Collaboration Research and Technology Licensing AgreementConfidential Treatment Requested • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
Contract Type FiledMarch 30th, 2015 Company IndustryThis Definitive Collaboration Research and Technology Licensing Agreement (this “Agreement”) is effective as of May 31, 2011 (the “Effective Date”), and is entered into by and between
SEVERANCE AGREEMENTSeverance Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
Contract Type FiledAugust 9th, 2024 Company Industry Jurisdiction
JOINT DEVELOPMENT & LICENSE AGREEMENTJoint Development & License Agreement • March 30th, 2015 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • England and Wales
Contract Type FiledMarch 30th, 2015 Company Industry JurisdictionThis Joint Development and License Agreement (this “Agreement”) is made as of November 21st, 2013 (the “Effective Date”), by and between Pieris AG, a German stock corporation organized and existing under the laws of Germany, whose principal place of business is at Lise-Meitner-Straße 30, 85354 Freising, Germany (“Pieris”), and Stelis BioPharma Private Limited, formerly known as Agila Biotech Private Limited, a company incorporated under the Companies Act (India), 1956 and having its registered office at Strides House, Bilekahalli, Bannerghatta Road, Bangalore 560 076, India (“Stelis BioPharma”). Pieris and Stelis BioPharma may be referred to individually as a “Party” or together as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED COLLABORATION AND LICENSE AGREEMENTConfidential Treatment Requested • December 18th, 2014 • Marika Inc. • Services-business services, nec
Contract Type FiledDecember 18th, 2014 Company IndustryThis COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into effective as of September 24th, 2010 (the “Effective Date”) by and between
CONFIDENTIAL TREATMENT REQUESTED DEFINITIVE LICENSE AND TRANSFER AGREEMENTConfidential Treatment Requested • August 11th, 2016 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledAugust 11th, 2016 Company Industry JurisdictionThis Definitive License and Transfer Agreement (the “Agreement”) is entered into with effect as of June 6, 2016 (the “Effective Date”) by and between Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively and together with their Affiliates, “Pieris”) and Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (together with its Affiliates, “Enumeral”).
AMENDED AND RESTATED MANAGEMENT AGREEMENT betweenManagement Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec
Contract Type FiledDecember 18th, 2014 Company IndustryWHEREAS, by resolution adopted by the Supervisory Board on December 17, 2009, the Executive was appointed to the Management Board to serve as Chairman of the Management Board (Vorstandsvorsitzender) of the Company for a term from January 1, 2010 to December 31, 2014.
Investment Agreement Pieris AG, Freising, Germany dated October 10, 2014 by and amongInvestment Agreement • December 18th, 2014 • Marika Inc. • Services-business services, nec
Contract Type FiledDecember 18th, 2014 Company Industry
Lease Agreement -Pieris Pharmaceuticals, Inc. • March 18th, 2019 • Services-commercial physical & biological research
Company FiledMarch 18th, 2019 Industry
NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE PALVELLA THERAPEUTICS, INC. COMPANY 2019 EQUITY INCENTIVE PLANNon-Qualified Stock Option Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 9th, 2024 Company Industry JurisdictionTHIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made between Palvella Therapeutics, Inc. Company, a Delaware corporation (the “Company”) and [________] (the “Optionee”).
Re: 3(a)(9) Exchange AgreementLetter Agreement • April 6th, 2020 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Contract Type FiledApril 6th, 2020 Company Industry JurisdictionThis letter agreement (the “Agreement”) confirms the agreement of Pieris Pharmaceuticals, Inc. (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 3,000,000 shares (the “Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”), beneficially owned by the Stockholders in consideration for a total of 3,000 shares of Series D Convertible Preferred Stock of the Company (the “Preferred Shares”), which shall have the rights, preferences and privileges set forth in the Certificate of Designation set forth on Exhibit A attached hereto (the “COD”). The Preferred Shares will be convertible into a total of 3,000,000 shares of Common Stock (subject to adjustment as provided in the COD), subject to beneficial ownership conversion limitations set forth in the COD.